Accumulating evidence indicates that gain-of-function mutations in the FGFR3 gene may give rise to constitutive receptor activation and have been identified in bladder cancer and UTUC [25,26,27,28,29]. Here, FGFR3 is linked to urinary bladder carcinoma.